Shareholder voteRegulatory filing
What was reported
On June 5, 2026, Prime Medicine, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) in a virtual meeting format via live webcast. Proxies were solicited pursuant to the Company’s definitive proxy statement (the “Proxy Statement”) filed on April 23, 2026 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended.U.S. Securities and Exchange Commission (EDGAR) · 8-K: 8-K · Jun 8, 2026 · Open the source ↗
What the evidence supports
Prime Medicine told the SEC (Form 8-K, Item 5.07) that its shareholders voted on matters put to them, and what the outcome was. The filing gives Jun 5, 2026 as the date of the earliest event reported.
What remains unknown
How individual shareholders voted, and what the company will do next beyond what it disclosed.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Form 8-K, Item 5.07 textOn June 5, 2026, Prime Medicine, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) in a virtual meeting format via live webcast. Proxies were solicited pursuant to the Company’s definitive proxy statement (the “Proxy Statement”) filed on April 23, 2026 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended.U.S. Securities and Exchange Commission (EDGAR) · 8-K: 8-K · Jun 8, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:52 UTC
Prime Medicine reports results of a shareholder vote (Form 8-K, Item 5.07)
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.